학술논문
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Document Type
Article
Author
Song, Y.; Malpica, L.; Cai, Q.; Zhao, W.; Zhou, K.; Wu, J.; Zhang, H.; Mehta-Shah, N.; Ding, K.; Liu, Y.; Li, Z.; Zhang, L.; Zheng, M.; Jin, J.; Yang, H.; Shuang, Y.; Yoon, D.H.; Gao, S.; Li, W.; Zhai, Z.; Zou, L.; Xi, Y.; Koh, Y.; Li, F.; Prince, M.; Zhou, H.; Lin, L.; Liu, H.; Allen, P.; Roncolato, F.; Yang, Z.; Kim, W.-S.; Zhu, J.
Source
In: The Lancet Oncology . (The Lancet Oncology, January 2024, 25(1):117-125)
Subject
Language
English
ISSN
14745488
14702045
14702045